top of page

Massachusetts Governor Maura Healey discusses keeping the state on top in life sciences, global competition, and more | 03/26/25

Play Video

TOP VIDEO: State of Possible: Massachusetts Governor Maura Healey discusses keeping the state on top in life sciences, global competition, and more | 03/26/25

Latest Videos

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs | 05/16/25

Play Video

From Cambridge, UK:

Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies

05/16/2025

Meet NewBiologix, an innovative Swiss biotech company dedicated to revolutionizing the field of gene therapy

Play Video

NewBiologix: An innovative Swiss biotech company dedicated to revolutionizing the field of gene therapy.

Sponsored

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 program for DMD in a Presidential Symposium talk | 05/15/25

Play Video

ASGCT 2025:

HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

05/15/2025

ASGCT 2025: Dyno Therapeutics CEO Eric Kelsic dicusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions | 05/15/25

Play Video

ASGCT 2025:

Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

05/15/2025

ASGCT 2025: Physicians and scientists raced to make a bespoke gene editing therapy for an infant who urgently needed one in months - a first hand account, and what this means for drug development | 05/15/25

Play Video

ASGCT 2025:

Physicians and scientists raced to make a bespoke gene editing therapy for an infant who urgently needed one in months - a first hand account

05/15//2025

Shows

SF Healthcare Week: Nicole Paulk shares an update on her company Siren Biotechnology and describes what the environment is like for smaller companies in biotech right now | 01/16/25

09:50

SF Healthcare Week: Nicole Paulk shares an update on her company Siren Biotechnology and describes what the environment is like for smaller companies in biotech right now | 01/16/25

She describes how Siren is being built with a universal AAV platform, and is nearing its first IND in oncology. Plus, the fundraising environment around this year's conference, and how gene therapy might be insulated from the competition from China that other areas have been feeling.

SF Healthcare Week: Chris Gibson talks the Exscientia merger, Recursion's scale and capabilities, and key targets | 01/15/25

12:06

SF Healthcare Week: Chris Gibson talks the Exscientia merger, Recursion's scale and capabilities, and key targets | 01/15/25

He discusses the merger that completed towards the end of last year, Recursion's computational and wet lab abilities, cerebral cavernous malformation, targets such as MALT1, LSD1, CDK7, and more.

SF Healthcare Week: Rachel Haurwitz shares an update on Caribou Biosciences' allo CAR-T programs in NHL, BCMA, and lupus programs | 01/15/25

11:05

SF Healthcare Week: Rachel Haurwitz shares an update on Caribou Biosciences' allo CAR-T programs in NHL, BCMA, and lupus programs | 01/15/25

She describes how the company's HLA matching and CD19 relapse testing is playing out, when we can expect to see new data, and how the lupus program is progressing.

SF Healthcare Week: Affinity Asset Advisors' Head of Research Patrick Nosker shares his take on Monday's conference news, and discusses some of his fund's top holdings | 01/13/25

09:45

SF Healthcare Week: Affinity Asset Advisors' Head of Research Patrick Nosker shares his take on Monday's conference news, and discusses some of his fund's top holdings | 01/13/25

He talks about todays M&A heavy news and the market reaction to it, and comments on Xenon, Madrigal, Nurix, and Wave.

SF Healthcare Week: The CEO of Arvians talks protein degradation, including about the industry's first phase 3 readout that is upcoming | 01/15/25

11:42

SF Healthcare Week: The CEO of Arvians talks protein degradation, including about the industry's first phase 3 readout that is upcoming | 01/15/25

John Houston describes what he believes are the keys to protein degradation, and discusses the company's monotherapy and combination approach in breast cancer. Plus, Parkinson's, hematology, and more.

SF Healthcare Week: Cytokinetics CEO Robert Blum describes preparing for the potential commercial launch of aficamten, an upcoming monotherapy trial readout, omecamtiv mecarbil, and more | 01/16/25

19:05

SF Healthcare Week: Cytokinetics CEO Robert Blum describes preparing for the potential commercial launch of aficamten, an upcoming monotherapy trial readout, omecamtiv mecarbil, and more | 01/16/25

He highlights the company's current clinical programs, and talks about how thy are leveraging for the future the unique expertise in muscle biology Cytokinetics has built over three decades.

SF Healthcare Week: Baird's Brian Skorney shares his take on this morning's conference news, the year ahead, and his top picks | 01/14/24

12:13

SF Healthcare Week: Baird's Brian Skorney shares his take on this morning's conference news, the year ahead, and his top picks | 01/14/24

He discusses news from Biogen and Regeneron, and shares his top picks Xenon, Soleno, and Lexeo.

SF Healthcare Week: Flagship Pioneering's Noubar Afeyan on Moderna, gov't policy, China, and "polyintelligence" in drug development | 01/13/25

15:58

SF Healthcare Week: Flagship Pioneering's Noubar Afeyan on Moderna, gov't policy, China, and "polyintelligence" in drug development | 01/13/25

He shares his thoughts on Moderna's transition, what policies he would like to see promoted in government, competing with China, and the multitude of factors (AI, human intelligence, nature) that must be included in the drug development process.

2025 SF Healthcare Week

Moderna CEO Stéphane Bancel walks us through Moderna and Merck's 3-year individual neoantigen therapy + Keytruda adjuvant melanoma data | 06/03/24

05:57

Moderna CEO Stéphane Bancel walks us through Moderna and Merck's 3-year individual neoantigen therapy + Keytruda adjuvant melanoma data | 06/03/24

At Moderna's analyst meeting at #ASCO24 in Chicago, Stéphane Bancel shows the Kaplan-Meier curve separation over time for the neoantigen platform in melanoma, and also discusses Moderna's intratumoral platform, and how mRNA can work with new modalities like bispecifics and cell therapies

The CEO of Cullinan Therapeutics discusses two data sets at #ASCO24 and the rationale for a T-cell engager for autoimmune disease | 06/01/24

14:06

The CEO of Cullinan Therapeutics discusses two data sets at #ASCO24 and the rationale for a T-cell engager for autoimmune disease | 06/01/24

Nadim Ahmed describes #ASCO24 data from today for CLN-619 and zipalertinib, and discusses taking a CD19/CD3 into the clinic for lupus.

Summit Therapeutics' Jack West on the company's PD-1xVEGF bi-specific vs Keytruda news | 06/01/24

16:02

Summit Therapeutics' Jack West on the company's PD-1xVEGF bi-specific vs Keytruda news | 06/01/24

V.P. of Clinical Operations Jack West gives his interpretation of the announcement that Summit's partner Akeso made in China that it beat Keytruda on PFS head-to-head in 1L lung. He shares his opinion of how this data could translate outside of China and what Summit's development plans are currently.

Nimbus Therapeutics CEO Jeb Keiper on the company's HPK1 data at #ASCO24 | 06/01/24

10:58

Nimbus Therapeutics CEO Jeb Keiper on the company's HPK1 data at #ASCO24 | 06/01/24

Jeb Keiper describes the HKP1 pathway and why he believes his company's expertise in precision engineering and machine learning has helped it discover and develop this asset.

Rachel Haurwitz on Caribou's #ASCO24 data and the rationale for taking time to look further at HLA matching for allo CAR-T | 06/03/24

15:15

Rachel Haurwitz on Caribou's #ASCO24 data and the rationale for taking time to look further at HLA matching for allo CAR-T | 06/03/24

Rachel Haurwitz elaborates on the data update for CB-010 that was presented at ASCO yesterday and describes why the company will push back the start of a pivotal trial approximately six months to better understand how HLA matching potentially affects efficacy.

Verastem Oncology's CEO comments on a volatile week and #ASCO24 data in pancreatic cancer | 06/02/24

12:29

Verastem Oncology's CEO comments on a volatile week and #ASCO24 data in pancreatic cancer | 06/02/24

Dan Paterson gives background on the rolling submission the company started this week in a type of ovarian cancer, with his thoughts on the market reaction, and highlights new data at ASCO this year.

ApexOnco's Jacob Plieth previews #ASCO24 | 05/31/24

19:23

ApexOnco's Jacob Plieth previews #ASCO24 | 05/31/24

From McCormick Place, Jacob Plieth previews key data from Merus, Summit, Iovance, Caribou, AstraZeneca, GSK, Gilead, and more.

Immunocore's CEO and Head of R&D discuss the company's PRAME data at #ASCO24 | 06/01/24

13:41

Immunocore's CEO and Head of R&D discuss the company's PRAME data at #ASCO24 | 06/01/24

Bahija Jallal and David Berman go over Immunocore's PRAME data in cutaneous melanoma and explain why they believe that the disease control rate they are seeing today could translate into a robust OS number in the future.

#ASCO24

ApexOnco's Jacob Plieth shares his take on what to watch for at the 2024 ASH Annual meeting | 12/7/24

14:22

ApexOnco's Jacob Plieth shares his take on what to watch for at the 2024 ASH Annual meeting | 12/7/24

He talks modalities and targets, and comments on Arcellx, Galapagos, BeiGene, Nurix, Kura, JNJ, Syndax, AbbVie AstraZeneca, CellCentric, and more.

Autolus CEO Christian Itin talks about the approval of of the CAR-T Aucatzyl, as well as the company's development pipeline (including autoimmune) | 12/7/24

13:56

Autolus CEO Christian Itin talks about the approval of of the CAR-T Aucatzyl, as well as the company's development pipeline (including autoimmune) | 12/7/24

He discusses Autolus' 'fast off' approach to CAR-T and why he believes the safety benefits led to no REMS requirement for Aucatzyl. Plus, ASH presentations, and how Autolus is the only company using a commercially approved CD19 construct in clinical trials for autoimmune disease.

ASH 2024: Kite Pharma's global head discusses the progress of the CAR-T field, Arcellx's BCMA data, cures in CD19, autoimmune, and future targets | 12/8/24

13:29

ASH 2024: Kite Pharma's global head discusses the progress of the CAR-T field, Arcellx's BCMA data, cures in CD19, autoimmune, and future targets | 12/8/24

Cindy Perettie describes why she took the head job at Kite a little over a year ago, long-term CD19 data, tonight's BCMA update, Kite's approach to autommite, a glioblastoma program, and more.

Legend CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more

12:34

Legend CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more

He discusses this year's Cartitude 4 approval, plus current studies in 1L multiple myeloma. Also, his take on a potential future competitors' data at ASH, other programs, including autoimmune, and plans for an R&D center in Philadelphia.

ASH 2024: The new CEO of Innate Pharma on taking the job and the company's work on antibodies, engagers, and ADCs | 12/7/24

09:41

ASH 2024: The new CEO of Innate Pharma on taking the job and the company's work on antibodies, engagers, and ADCs | 12/7/24

Jonathan Dickinson describes what appealed to him about Innate. He discusses the pipeline, including ASH data from the lead program Lacutamab and an NK engager program Sanofi is partnered on.

ASH 2024: BeiGene CEO John Oyler on degraders, long-term BTK data, BCL2 inhibition, and being a global company | 12/8/24

14:12

ASH 2024: BeiGene CEO John Oyler on degraders, long-term BTK data, BCL2 inhibition, and being a global company | 12/8/24

He describes the different profile of degraders vs small molecules, and highlights BeiGene's programs in BTK, EGFR, IRAK4, and others. Plus ASH data for Brukinsa and a BLC2, and how BeiGene's investments in global scale are bearing fruition.

ASH 2024: Incyte CEO Hervé Hoppenot on the company's hematology franchise and keeping up the momentum in 2025 | 12/8/24

11:37

ASH 2024: Incyte CEO Hervé Hoppenot on the company's hematology franchise and keeping up the momentum in 2025 | 12/8/24

He comments on data at ASH including tafasitamab, axitilimab, and the company's BET inhibitor. Plus, news from yesterday on Incyte's PD1, and looking forward to next year.

Cambridge, UK based CellCentric has a unique approach to targeting p300/CBP and thus reducing the activation of oncogenes like IRF4 and MYC in multiple myeloma | 12/7/24

06:43

Cambridge, UK based CellCentric has a unique approach to targeting p300/CBP and thus reducing the activation of oncogenes like IRF4 and MYC in multiple myeloma | 12/7/24

CEO Will West describes how the company focuses on inhibiting the bromodomain of these targets with inobrodib, rather than the active sites, and how this is different than the approaches of other companies. He describes CellCentric's phase 2 data at ASH and the next steps for the program.

#ASH24

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page